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Abstract
Prader-Willi syndrome (PWS) is a genetic disorder caused by a mutation of 
chromosome 15, resulting in infantile hypotonia, obesity, short stature, 
mild-to-moderate mental retardation and neuroendocrinological abnor-
malities. A number of behavioral and psychiatric problems such as temper 
tantrums, self-injurious behavior, impulsiveness, lability of mood, attention 
deficit and hyperkinetic disorder symptoms, obsessive compulsive disorder 
and autistic spectrum disorder are associated with the syndrome. We report 
two adolescents with PWS who manifested psychiatric and behavioral 
problems and received psychopharmacological treatment. A 14-year-old 
boy had the uniparental disomy type of Prader-Willi syndrome and mani-
fested attention deficit hyperactivity disorder symptoms, uncontrollable 
eating behavior and conduct disorder. A 15-year-old boy had the deletion 
type of PWS with attention deficit hyperactivity disorder symptoms and 
autistic spectrum symptoms. The two adolescents were both prescribed 
methylphenidate and sertraline hydrochloride. The present report shows 
the efficacy and side effects of psychotropic medications in Prader-Willi 
syndrome. [Tzu Chi Med J 2010;22(1):43–46]
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1. Introduction
Prader-Willi syndrome (PWS) is a rare genetically deter-
mined condition, which has an estimated prevalence 
of 1/10,000–1/15,000. The four genetic classes of 
PWS are: (1) maternal uniparental disomy (UPD) for 
chromosome 15; (2) 3–4 MB deletion of the paternally 
inherited 15q11-13 region; (3) paternally inherited 
balanced translocation involving this region; and (4) im-
printing mutations or deletions of the PWS imprinting 
center. Approximately 25–30% of patients with PWS 
present with UPD for maternal chromosome 15 and 
60–70% of patients have deletion of 15q11-13 on the 
paternal chromosome [1–5].
PWS is now considered a multistage disorder char-
acterized by three different phases [6]. The first phase, 
“the hypotonic phrase”, is characterized by varying de-
grees of hypotonia during the neonatal and early in-
fancy periods. The second phase, “the hyperphagic 
phase”, which usually starts between the age of 1 and 
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2 years, is characterized by a voracious appetite, hyper-
phagia, foraging for food, obesity, speech and articula-
tion difficulties and cognitive dysfunction. In addition, 
individuals with PWS show significant maladaptive be-
havioral and emotional characteristics including tem-
per tantrums, inappropriate social behaviors, skin 
picking, stubbornness, mood lability, impulsivity, de-
pression, anxiety and obsessive-compulsive symptoms 
[7–10] and autistic spectrum disorder [11–13]. Wigren 
and Hansen [2] reported that 22% of 58 individuals 
with PWS (aged 5–18 years) had significant problems 
with attention deficit, hyperactivity, impulsivity and 
some conduct problems. The third phase, “adolescence 
and adulthood”, is dominated by health problems sec-
ondary to obesity, including scoliosis, diabetes mel-
litus, and hypercholesterolemia [14]. Approximately 
10% of the adolescents and adults develop major 
psychiatric problems ranging from affective disorder 
to psychotic episodes [15–19].
Because of the numerous psychiatric illnesses in 
people with PWS, psychotropic medications such as 
antipsychotics, antidepressants and mood-stabilizing 
agents are often used [19]. There are few reports 
[20,21] of methylphenidate use in PWS in patients 
with attention deficit hyperactivity disorder (ADHD) 
symptoms. We present two cases of adolescents given 
a combination of a psychostimulant (methylphenidate) 
and an antidepressant (sertraline hydrochloride).
2. Case reports
2.1. Case 1
Case 1 was a 14-year-old boy who was born after an 
uneventful pregnancy but was premature at 36 weeks 
of gestation and suffered from neonatal hypoxia. He 
walked at 2 years and 5 months, spoke his first word 
at age 3 years and spoke sentences at age 4 years. 
The results of chromosomal and molecular examina-
tion confirmed the diagnosis of PWS UPD. He also had 
diabetes mellitus controlled by metformin and gli-
clazide. His body weight was 54.2 kg and his body 
height was 155 cm. He was referred to the department 
of psychiatry because of conduct problems.
The patient had stolen bicycles, mobile phones and 
food even after being punished by his parents. He 
also told lies, denied every charge against him, and 
manifested repetitive speech, poor emotional control, 
temper tantrums and physical aggression toward his 
classmates. He showed poor attention and concentra-
tion, was easily distracted, had been very hyperactive 
for years and had become oppositional in the previous 
year. The Chinese version of the Swanson, Nolan and 
Pelham, Version IV scale for ADHD-parents (SNAP IV) 
was administered and he obtained a score of 17 in the 
inattention subscale (90–95th percentile), 10 in the 
hyperactivity–impulsivity subscale (85–90th percentile) 
and 24 in the oppositional subscale (99th percentile) 
[22]. In the Chinese version of the Wechsler Intel-
ligence Scale for Children-III he had a full-scale IQ of 
53, verbal IQ of 66 and performance IQ of 47.
The patient was diagnosed with ADHD, conduct 
disorder and mild mental retardation. Methylphenidate 
18 mg one tablet per day (Concerta; Alza Pharmaceu-
ticals, Mountain View, CA, USA) was initially prescribed 
and behavior modification using token economy was 
implemented to eliminate his conduct problems. Three 
months later, he had no more conduct problems. The 
Chinese version of the SNAP IV was administered again 
and he obtained a score of 5 in the inattention sub-
scale (30th percentile), 5 in the hyperactivity–impulsivity 
subscale (65th percentile) and 8 in the oppositional 
sub scale (80th percentile). However, owing to his skin-
picking, temper tantrums and uncontrollable eating be-
havior, sertraline hydrochloride (Zoloft; Pfizer U.S. 
Pharmaceuticals Group, New York, NY, USA) was pre-
scribed and his mother reported that he began to 
show better emotional control, and had less skin-pick-
ing behavior, but still ate too much.
One year later, he started to show self-talking and 
the severity of skin-picking increased. The symptoms 
subsided after discontinuation of methylphenidate. 
He remained on sertraline hydrochloride 50 mg 2 
tablets per day for 6 months. He then began to have 
reference delusions in which some classmates in-
sulted him and he manifested physical aggression 
toward his mother and classmates. Risperidone 
0.5 mg was prescribed and his psychotic symptoms 
showed great improvement.
2.2. Case 2
Case 2 was a 15-year-old boy who was born via cesar-
ean section after an uneventful pregnancy, but he had 
neonatal hypoxia. He spoke his first word at age 3 
years and walked at age 4 years. Chromosomal and 
molecular examination established the diagnosis of 
PWS, deletion type. He received growth hormone ther-
apy for half a year but treatment was discontinued 
because of hip complications. His body weight was 
54.2 kg and his body height was 143.5 cm. He was 
referred to the department of psychiatry because of 
temper tantrums. A family history revealed that his 
father had bipolar illness.
The patient showed some autistic spectrum symp-
toms, such as poor social skills, lack of empathy, and 
repetition of behaviors and questions, and he repeat-
edly rearranged objects on his desk and changed 
clothes until he felt “just right”. He had temper tan-
trums if there were any changes in his daily routine. 
He also had stereotyped thinking, and excellent recall 
of telephone numbers and names. He showed poor 
 TZU CHI MED J  March 2010  Vol 22  No 1 45
attention and concentration, was easily distracted, 
and had been very hyperactive and oppositional for 
years. The Chinese version of the SNAP IV was admin-
istered and he obtained scores of 19 in the inattention 
subscale (95–99th percentile), 23 in the hyperactivity–
impulsivity subscale (over 99th percentile) and 24 in 
the oppositional subscale (over 99th percentile) [22]. 
The Chinese version of the Wechsler Intelligence Scale 
for Children-III yielded a full-scale IQ of 55, verbal IQ 
of 69 and performance IQ of 48.
The patient was diagnosed with ADHD and mild 
mental retardation, and methylphenidate 18 mg one 
tablet per day (Concerta; Alza Pharmaceuticals) was 
prescribed. A follow-up administration of the Chinese 
version of the SNAP IV yielded scores of 16 in the 
inattention subscale (90–95th percentile), 19 in the 
hyperactivity–impulsivity subscale (95–99th percentile) 
and 14 in the oppositional subscale (95th percentile). 
His mother felt that his inattention and hyperactive 
symptoms had moderately improved. Five weeks later, 
because of temper tantrums and compulsive repetitive 
speech that disrupted his interpersonal relationships, 
sertraline hydrochloride 50 mg per day was prescribed. 
One month after administration of antidepressant med-
ication, he began to have a decreased need for sleep, 
became hypertalkative, manifested an irritable mood 
and threatened his family with a knife. Medication-
induced mood disorder (manic episode) was sus-
pected and he was admitted to an acute psychiatric 
ward where carbamazepine 200 mg one tablet three 
times per day (Tegretol; Novartis Pharmaceuticals Corp., 
East Hanover, NJ, USA) was prescribed. After discharge, 
the patient remained on carbamazepine and methyl-
phenidate for irritable mood and ADHD symptoms.
3. Discussion
Wigren et al [2] found that one fourth of patients with 
PWS show clinical indices of ADHD, which are highly as-
sociated with maladaptive conduct problems. Je rome 
[20] reported a case of PWS with marked features of 
attention deficit disorder, which was treated with 
methylphenidate 60 mg a day in divided doses. Meth-
ylphenidate has been widely studied among mentally 
retarded children with ADHD and in children with 
Fragile X syndrome [23].
Our patients with different types of PWS both 
showed ADHD symptoms diagnosed with the Chinese 
version of the SNAP IV. They were both treated with 
low dose methylphenidate (0.33 mg/kg of body 
weight) and both showed good responses in each of 
the three domains assessed by the SNAP IV scales, 
i.e. inattention, hyperactivity–impulsivity and opposi-
tional domains. However, Case 1, who had the UPD 
type of PWS, later developed self-talking and increased 
severity of skin-picking and the symptoms subsided 
after discontinuation of methylphenidate. Case 2, 
who had the deletion type of PWS, has remained 
on methylphenidate for inattention and impulsivity. 
Selective serotonin reuptake inhibitors are frequently 
used in PWS for several different psychopathologies, 
including skin-picking, food intake-related behav-
iors, depressive disorder and obsessive-compulsive 
symptoms [19].
The symptoms of poor emotional control and skin-
picking in Case 1 were well-controlled by sertraline for 
more than 1 year, but he developed psychotic symp-
toms later. Studies by Boer et al [24] and Vogels et al 
[25] demonstrated a relatively high rate of affective 
psychosis in adolescents with PWS, especially in sub-
jects with UPD.
After taking sertraline for temper tantrums for 1 
month, Case 2 manifested an episode of suspected 
drug-induced mania, and carbamazepine was used 
to control his emotional dysregulation. Hergüner and 
Mukaddes [26] reported a case of fluoxetine-induced 
psychosis in a patient with PWS. After discontinuation 
of sertraline use, Case 2 did not show any episodes 
of mania and he has been able to attend a vocational 
high school. In a larger study of PWS in the United 
Kingdom [19], 24/85 (28.2%) individuals with the 
deletion type of PWS had a history of psychopatholo-
gies including non-psychotic depressive illness, depres-
sive psychosis and psychotic illness. No one with the 
deletion type of PWS had bipolar illness. Thus, we sus-
pect that Case 2 in our study might have had selective 
serotonin reuptake inhibitor-induced mania, probably 
associated with his family history of bipolar disorder.
In conclusion, PWS usually manifests numerous 
phenotypes, such as psychiatric symptoms ranging 
from autistic spectrum disorder to attention deficit 
hyperkinetic disorder, and from obsessive-compulsive, 
affective disorder to psychosis. Therefore, psycho-
pharmacological treatment is important, but the side 
effects of medications must be carefully monitored 
because different psychopathologies might manifest 
themselves in the course of the illness.
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